Skip to main content

8-K

Japan Food Tech Holdings, Inc. (JFTH)

8-K 2022-02-23 For: 2022-02-22
View Original
Added on May 29, 2026

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

**Washington,D.**C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the SecuritiesExchange Act of 1934

Date of Report (Date of Earliest Event Reported): February 22, 2022

Dr. Foods, Inc.<br><br> <br>****
(Exact name of registrant as specified in its charter)
Nevada 000-56277 00-0000000
--- --- ---
(state or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification Number)
3F K’s Minamiaoyama<br><br> <br>6-6-20 Minamiaoyama, Minato-ku,<br><br> <br>Tokyo 107-0062, Japan 107-0062
--- ---
(address of principal executive offices) (zip code)
81-90-6002-4978
---
(registrant’s telephone number, including area code)
N/A
---
(former name or former mailing address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[   ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[   ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[   ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[   ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  [X]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  [   ]

“We”, “Us”, and or “The Company” refer to Dr. Foods, Inc.

ForwardLooking Statements


This Current Report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks, uncertainties, and assumptions that are difficult to predict. All statements other than statements of historical fact contained in this Current Report, including statements regarding future events, our future financial performance, business strategy, and plans and objectives of management for future operations, are forward-looking statements. We have attempted to identify forward-looking statements by terminology including “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” or “should,” or the negative of these terms or other comparable terminology. The forward-looking statements made herein are based on the Company’s current expectations. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, its limited operating history, competitive factors in the Company’s industry and market, and other general economic conditions. The forward-looking statements made herein are based on the Company’s current expectations, assumptions, and projections, which could provide to be incorrect. The forward-looking statements made herein speak only as of the date of this Current Report and the Company undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

ITEM5.03 AMENDMENTS TO ARTICLES OF INCORPORATION OR BYLAWS.

Our majority shareholders, collectively, White Knight Co., Ltd. and Next Meats Holdings, Inc., and our Board of Directors, have executed a resolution to ratify, affirm, and approve an amendment to our Certificate of Incorporation, increasing the authorized shares of our Common Stock from 2,400,000,000 to 4,800,000,000. The Amendment was filed with the Nevada Secretary of State on February 22, 2022, effective immediately upon filing.

The Company believes that this action to increase the authorized shares of available common shares will allow the Company, amongst other things, and if it so chooses, to more easily garner investments from future capital raises through the sale of equity.

A copy of the amendment to our certificate of incorporation is attached herein as exhibit 3.12.

Item 9.01 Exhibits.


Exhibit Number Description of Exhibit
3.1 Certificate of Incorporation (1)
3.11 Certificate of Amendment (2)
3.12 Certificate<br> of Amendment (3)

(1) Filed as an exhibit to the Company’s Form 10-12G, as filed with the SEC on May 3, 2021, and incorporated herein by this reference.

(2) Filed as an exhibit to the Company’s 8-K, as filed with the SEC on August 25, 2021, and incorporated herein by this reference.

(3) Filed herewith.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.

Dr.<br> Foods, Inc.
Dated:<br>  February 23, 2022 /s/ Koichi Ishizuka
Koichi Ishizuka<br><br> <br>Chief Executive Officer

ARTICLE IV

CAPITAL STOCK

The total number of shares of capital stock which the Corporation shall have authority to issue is: four billion eight hundred twenty million (4,820,000,000). These shares shall be divided into two classes with four billion eight hundred million (4,800,000,000) shares designated as common stock at $0.0001 par value (the "Common Stock") and twenty million (20,000,000) shares designated as preferred stock at $0.0001 par value (the "Preferred Stock").

Designation of Preferred Series Z stock. Ten Thousand (10,000) shares of the Company’s preferred stock shall be designated as Series Z Preferred Stock, $0.0001 par value per share. Initially, there will be no dividends due or payable on the Series Z Preferred Stock. Holders of Series Z Preferred Stock shall have no right to convert those shares into Common Stock or any other class of securities of the Corporation. Each one share of the Series Z Preferred Stock shall have voting rights equal to one million (1,000,000) votes of Common Stock. With respect to all matters upon which stockholders are entitled to vote or to which stockholders are entitled to give consent, the holders of the outstanding shares of Series Z Preferred Stock shall vote together with the holders of Common Stock without regard to class, except as to those matters on which separate class voting is required by applicable law or the Corporation’s Certificate of Incorporation or by-laws.

Preferred Stock. The Preferred Stock of the Corporation shall be issuable by authority of the Board of Director(s) of the Corporation in one or more classes or one or more series within any class and such classes or series shall have such voting powers, full or limited, or no voting powers, and such designations, preferences, limitations or restrictions as the Board of Directors of the Corporation may determine, from time to time. The authority of the Board of Directors with respect to each class or series shall include all designation rights conferred by Nevada Laws upon directors, including, but not limited to, determination of the following:

(a) The number of shares constituting of that class or<br> series and the distinctive designation of that class or<br><br> <br>series;
(b) The dividend rate on the share of that class or series,<br> whether dividends shall be cumulative, and, if so,<br><br> <br>from which date or dates, and the relative rights<br> or priorities, if any, of payment of dividends on shares<br><br> <br>of that class or series;
--- ---
(c) Whether the shares of that class or series shall have<br> conversion privileges, and, if so, the terms and<br><br> <br>conditions of such privileges, including provision<br> for adjustment of conversion rate(s) in relation to such<br><br> <br>events as the Board of Directors shall determine;
--- ---

(d) Whether the shares of that class or series shall be redeemable, and, if so, the terms and conditions of such redemption, including the date or dates upon or after which amount they shall be redeemable, and the amount per share payable in case of redemption, which amount may vary under different conditions and at different redemption dates;

(e) Whether there shall be a sinking fund for the redemption or purchase of shares of that class or series, and, if so, the terms and amount of such sinking fund;

(f) The rights of the shares of that class or series in the event of voluntary or involuntary liquidation, dissolution or winding up of the Corporation, and the relative rights of priority, if any, of payment of shares of that class or series; and

(g) Any other relative rights, preferences and limitations of that class or series now or hereafter permitted by law.

Holders of shares of Common Stock shall be entitled to cast one vote for each share held at all stockholders' meetings for all purposes, including the election of directors. The Common Stock does not have cumulative voting rights.

No holder of shares of stock of any class or series shall be entitled as a matter of right to subscribe for or purchase or receive any part of any new or additional issue of shares of stock of any class or series, or of securities convertible into shares of stock of any class or series, whether now hereafter authorized or whether issued for money, for consideration other than money, or by way of dividend.